Postow, M. A., Cardona, D. M., Taube, J. M., Anders, R. A., Taylor, C. R., Wolchok, J. D., . . . Sznol, M. (2014). Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. BioMed Central.
Chicago Style CitationPostow, Michael A., et al. Peripheral and Tumor Immune Correlates in Patients With Advanced Melanoma Treated With Nivolumab (anti-PD-1, BMS-936558, ONO-4538) Monotherapy or in Combination With Ipilimumab. BioMed Central, 2014.
MLA CitationPostow, Michael A., et al. Peripheral and Tumor Immune Correlates in Patients With Advanced Melanoma Treated With Nivolumab (anti-PD-1, BMS-936558, ONO-4538) Monotherapy or in Combination With Ipilimumab. BioMed Central, 2014.